New imaging agent aims to light up Hard-to-Find cancers
NCT ID NCT07052760
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 111In-ABD147 (a radioactive imaging agent)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a new drug combo tame resistant prostate cancer?
- Can a genetic trait stop chemotherapy from working? a trial aims to fix that
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- AI could outshine standard tumor measurements to predict survival
- Old drug, new hope: niclosamide combo targets resistant prostate cancer